Id: acc3631
Group: 1sens
Protein: myosin light chain 20
Gene Symbol: MYL2
Protein Id: P10916
Protein Name: MLRV_HUMAN
PTM: phosphorylation
Site: Ser19
Site Sequence: AGGANSNVFSMFEQTQIQEFK
Disease Category: Cardiovascular and circulatory system diseases
Disease: Subarachnoid Hemorrhage
Disease Subtype: Subarachnoid Hemorrhage-Related Vasospasm
Disease Cellline: aortic SMCs
Disease Info:
Drug: Fasudil
Drug Info: "Fasudil is a drug used in medical treatment, which may have effects on certain physiological processes."
Effect: modulate
Effect Info: "Fasudil reduces the phosphorylation level of myosin by inhibiting related kinases (such as MLCK and ROCK), thus alleviating or preventing the vasospasm caused by subarachnoid hemorrhage from a mechanistic perspective."
Note:
Score: 4.0
Pubmed(PMID): 10448094
Sentence Index:
Sentence:

Sequence & Structure:

MAPKKAKKRAGGANSNVFSMFEQTQIQEFKEAFTIMDQNRDGFIDKNDLRDTFAALGRVNVKNEEIDEMIKEAPGPINFTVFLTMFGEKLKGADPEETILNAFKVFDPEGKGVLKADYVREMLTTQAERFSKEEVDQMFAAFPPDVTGNLDYKNLVHIITHGEEKD

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

Target Drug name MOA Phase Status Disease Source
MYL2 MAVACAMTEN Cardiac myosin inhibitor 4 - cardiovascular disease ATC
MYL2 MAVACAMTEN Cardiac myosin inhibitor 4 - hypertrophic cardiomyopathy FDA
MYL2 MAVACAMTEN Cardiac myosin inhibitor 4 Recruiting hypertrophic cardiomyopathy ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 3 Recruiting hypertrophic cardiomyopathy ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 3 Active, not recruiting hypertrophic cardiomyopathy ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 3 Completed hypertrophic cardiomyopathy ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 3 Completed heart failure ClinicalTrials
ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 3 Completed Reduced left ventricular ejection fraction ClinicalTrials
MYL2 DANICAMTIV Cardiac myosin activator 2 Terminated dilated cardiomyopathy ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 2 Active, not recruiting hypertrophic cardiomyopathy ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 2 Completed hypertrophic cardiomyopathy ClinicalTrials
ClinicalTrials
ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 2 Completed heart failure ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 2 Withdrawn heart failure ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 2 Terminated heart failure ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 2 Completed heart failure ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 2 Completed Reduced left ventricular ejection fraction ClinicalTrials
MYL2 MAVACAMTEN Cardiac myosin inhibitor 1 Completed hypertrophic cardiomyopathy ClinicalTrials
ClinicalTrials
MYL2 OMECAMTIV MECARBIL Cardiac myosin activator 1 Completed heart failure ClinicalTrials
ClinicalTrials

Note: Only show clinically investigational or approved drugs with protein targets.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC
MYL2-Ser19
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD

No data.

PTM-Drug Perturbation Response:

source: DecryptM

No data.

Function score:

source: funscoR

No data.

Cross Links: